Cytokinetics, Inc.

635 articles about Cytokinetics, Inc.

• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 10, 2022

  1/10/2022

  Cytokinetics, Incorporated announced that on December 31, 2021 it granted stock options to purchase an aggregate of 90,000 shares of common stock to 9 new employees, whose employment commenced in December 2021, as a material inducement to their employment.

• Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million

  1/7/2022

  Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten.

• Cytokinetics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

  1/3/2022

  Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 pm ET.

• Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics

  12/20/2021

  Cytokinetics, Incorporated (Nasdaq: CYTK) and Ji Xing Pharmaceuticals Limited today announced an expansion of their collaboration by entering into an exclusive license and collaboration agreement to develop and commercialize omecamtiv mecarbil for the proposed treatment of heart failure with reduced ejection fraction (HFrEF) in Greater China.

• Cytokinetics Announces Data From Its ALS Program Presented at the 32nd International Symposium on ALS/MND Majority of Initial Patients Enrolled in COURAGE-ALS Show Intended Middle to Fast Disease Progression Phenotype at Baseline

  12/10/2021

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 32nd International Symposium on ALS/MND including an analysis of baseline characteristics from the initial patients enrolled in COURAGE-ALS.

• Cytokinetics Announces Receipt of Breakthrough Therapy Designation from FDA for AficamtenFDA Granted Designation for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy Based on Results of REDWOOD-HCM

  12/9/2021

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 01, 2021

  12/1/2021

  Cytokinetics, Incorporated announced that on November 30, 2021 it granted stock options to purchase an aggregate of 143,500 shares of common stock to 9 new employees, whose employment commenced in November 2021, as a material inducement to their employment.

• Cytokinetics Announces Four Presentations at the 32nd International Symposium on ALS/MND

  11/30/2021

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one oral presentation and three poster presentations at the 32nd International Symposium on ALS/MND taking place online from December 7 – December 10, 2021.

• Cytokinetics Announces Additional Results from GALACTIC-HF Presented at American Heart Association Scientific Sessions 2021  

  11/15/2021

  Cytokinetics, Incorporated announced that additional results from GALACTIC-HF, the Phase 3 clinical trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction, were presented by Dr. John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HF, at the American Heart Association Scientific Sessions 2021.

• Cytokinetics Announces Two Presentations at the AHA Scientific Sessions 2021

  11/8/2021

  Cytokinetics, Incorporated announced two presentations at the American Heart Association Scientific Sessions 2021, taking place online from November 13, 2021 – November 15, 2021, including the presentation of additional results from GALACTIC-HF assessing the effect of omecamtiv mecarbil on stroke in patients with heart failure with reduced ejection fraction, and the presentation of preclinical data relating to a cardiac troponin activator that is a closely related analog to CK-3828136.

• Cytokinetics Reports Third Quarter 2021 Financial Results

  11/3/2021

  Submission of NDA for Omecamtiv Mecarbil on Track to Occur in Q4 2021 Start-Up Activities Underway for SEQUOIA-HCM Enrollment Complete in Cohort 3 of REDWOOD-HCM; Results Expected in Q1 2022

• Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) - Nov 01, 2021

  11/1/2021

  Cytokinetics, Incorporated announced that on October 29, 2021 it granted stock options to purchase an aggregate of 68,550 shares of common stock to 8 new employees, whose employment commenced in October 2021, as a material inducement to their employment.

• Cytokinetics Announces Preclinical Data Relating to CK-3828136 Presented at the 2021 Medicinal Chemistry Gordon Research Conference

  10/29/2021

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data relating to the discovery and optimization of CK-3828136 (CK-136) were presented at the 2021 Medicinal Chemistry Gordon Research Conference in West Dover, VT.

• Cytokinetics Announces Preclinical Data for CK-3828136 to Be Presented at the 2021 Medicinal Chemistry Gordon Research Conference

  10/21/2021

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to the discovery and optimization of CK-3828136 (CK-136) will be presented at the 2021 Medicinal Chemistry Gordon Research Conference.

• Cytokinetics to Announce Third Quarter Results on November 3, 2021

  10/20/2021

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2021 at 4:00 PM Eastern Time.

• Cytokinetics Outlines Go-To-Market Strategy for Omecamtiv Mecarbil and Provides Updates on Cardiovascular Pipeline at Today’s Analyst & Investor Day

  10/7/2021

  Clinical Trial Design Announced for SEQUOIA-HCM,  Phase 3 Clinical Trial of Aficamten Expected to Begin in Q4 Company Details Plan for Developing a Cardiovascular Franchise

• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021

  10/1/2021

  Cytokinetics, Incorporated announced that on September 30, 2021 it granted stock options to purchase an aggregate of 206,300 shares of common stock to 14 new employees, whose employment commenced in September 2021, as a material inducement to their employment.

• Cytokinetics Announces Fourth Annual Communications Fellowship Grant Program Call for Proposals

  9/28/2021

  Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases

• Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting

  9/12/2021

  Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten  Supporting Progression to Phase 3 Clinical Trial Additional Results from GALACTIC-HF Show Effect of Treatment with Omecamtiv Mecarbil  in Black Patients Consistent with Overall Population and White Patients Cytokinetics to Host Investor/Media Event and Webcast  on September 13, 2021 at 8:30 AM Eastern Time SOU

• Cytokinetics to Participate in September 2021 Investor Conferences

  9/8/2021

  Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences in September.